Thursday, 19 September

From Clinical Trials to Rwd With Faricimab: What You See is What You Get
19 September, 13:30 – 14:30 CEST
113/114
Chairperson(s):
A. Khanani, USA

A Turning Point in nAMD
19 September, 13:30 – 14:30 CEST
112
Chairperson(s):
R. Gale, UK
Friday, 20 September

EURETINA IME Platform on Dry AMD & GA: Implementing Modern Diagnosis and Management Approaches in Today’s Practice
20 September, 09:45 - 10:45 CEST
116/117
Chairperson(s):
A. Loewenstein, ISRAEL

Alcon Eye to Eye: Innovation, Precision & Integration
20 September, 09:45 - 10:45 CEST
113/114
Chairperson(s):
G. Pertile, ITALY

The Real World Impact of Faricimab on Clinic Capacity
20 September, 09:45 - 10:45 CEST
115
Chairperson(s):
D. Wong, CANADA

Optogenetic Therapies For Retinal Degenerative Disease – Clinical Developments And Updates
20 September, 09:45 - 10:45 CEST
118/119
Chairperson(s):
J. Monés, SPAIN,
F. Bandello, ITALY (Co-Chair)

Recent Advancements in Diagnosis & Management of X-linked Retinitis Pigmentosa
20 September, 09:45 - 10:45
212
Chairperson(s):
B. Leroy, BELGIUM

Advancing Retina Disease Management – Part 1: the Crucial Role of Diagnostic Imaging Today and Tomorrow
20 September, 13:45 - 14:45 CEST
111
Chairperson(s):
M. Munk, SWITZERLAND

A Turning Point in DME
20 September, 13:45 - 14:45 CEST
112
Chairperson(s):
M. Stewart, USA

Changing the nAMD Game Plan with Faricimab: Dual Pathway, Drying and Durability.
20 September, 13:45 - 14:45 CEST
211
Chairperson(s):
F. Holz, GERMANY

Imaging Innovations - Advancing Research and Patient Care
20 September, 13:45 - 14:45 CEST
212
Chairperson(s):
C. Mody, GERMANY

All Eyes on Geographic Atrophy
20 September, 17:45 - 18:45 CEST
112
Chairperson(s):
S. Bakalash, USA

Controversies on modern laser treatments for retina and vitreous
20 September, 17:45 - 18:45 CEST
115
Chairperson(s):
A. Filloy, SPAIN

Changing the DME Game Plan With Faricimab: Dual Pathway, Drying and Durability
20 September, 17:45 - 18:45 CEST
111
Chairperson(s):
P. Scholttmann, ARGENTINA

The Treatment of Neovascular AMD. Introducing Bevacizumab Gamma – the First Approved Ophthalmic Formulation of Bevacizumab
20 September, 17:45 - 18:45 CEST
212
Chairperson(s):
F. Bandello, ITALY
Saturday, 21 September

EURETINA IME Platform on Digital Visualization: New Technologies Bring Key Improvements to the Real World
21 September, 10:15 - 11:15 CEST
116/117
Chairperson(s):
G. Pertile, ITALY

Elevating Patient Outcomes With Single Capture Ultra-Widefield Imaging
21 September, 10:15 - 11:15 CEST
115
Chairperson(s):
S. Sadda, USA

Two Year Benefits in Clinical and Anatomical Measures in Intermediate Dry AMD Patients Treated With the Valeda Light Delivery System
21 September, 10:15 - 11:15 CEST
111
Chairperson(s):
M. Munk, SWITZERLAND

Clinical Insights on Retinal Morphology and Function With Deep Learning and Algorithms
21 September, 10:15 - 11:15 CEST
212
Chairperson(s):
T. Sakamoto, JAPAN

GA Patient Management for Tomorrow
21 September, 13:00 - 14:00 CEST
116/117
Chairperson(s):
A. Loewenstein, ISRAEL,
F. Holz, GERMANY

Protection of Vision and Structure in GA
21 September, 13:00 - 14:00 CEST
113/114
Chairperson(s):
U. Chakravarthy, IRELAND

Is Continuous Drug Delivery the Key to Transforming Long-term Outcomes in Retinal Diseases?
21 September, 13:00 - 14:00 CEST
115
Chairperson(s):
M. Figueroa, SPAIN

Advancing Retina Disease Management – Part 2: Managing Complicated Cases in Vitreoretinal Surgery
21 September, 13:00 - 14:00 CEST
111
Chairperson(s):
P. Stalmans, BELGIUM

Up for debate: points of view in retinal care
21 September, 13:00 - 14:00 CEST
112
Chairperson(s):
J. Kitchens, USA, P. Patel, UK

Improving on the Standard of Care in nAMD: Addressing the VEGF-C and -D Pathways
21 September, 13:00 - 14:00 CEST
211
Chairperson(s):
A. Khanani, USA

A Fully Immersive Visualization Experience
21 September, 13:00 - 14:00 CEST
212
Chairperson(s):
C. Mateo, SPAIN